See the DrugPatentWatch profile for Retavase
What is Retavase, and what is it used for?
Retavase is a thrombolytic medicine (a “clot-busting” drug) used to dissolve blood clots in certain heart-related emergencies. It contains reteplase, a genetically engineered form of tissue plasminogen activator (tPA) that helps convert plasminogen to plasmin, which breaks down fibrin in clots.
Clinically, it is used for thrombolysis in acute myocardial infarction (heart attack), typically when rapid clot dissolution is needed and per local protocols.
How does Retavase work?
Retavase’s active ingredient, reteplase, promotes clot breakdown by increasing plasmin formation. Plasmin then degrades fibrin, the main structural component of a blood clot, which can restore blood flow through blocked coronary arteries.
How is Retavase given?
Retavase is administered as an intravenous injection. In many protocols, it is delivered as a dosing regimen given in two IV boluses, separated by a short interval, but exact timing and dose can depend on the product label and local practice.
What side effects are associated with Retavase?
The best-known risk with thrombolytics like Retavase is bleeding, including serious or life-threatening bleeding. Other possible adverse effects can include:
- bleeding at injection or catheter sites
- allergic-type reactions
- reperfusion-related complications (from restoring blood flow)
Who should not take Retavase (key risk factors)?
Trombolytics are generally avoided in people with conditions that raise the risk of dangerous bleeding. Contraindications and “high risk” situations can include recent major surgery or trauma, a history of intracranial bleeding, and other bleeding disorders or active bleeding, depending on the specific prescribing information.
What happens if Retavase doesn’t work?
If clot lysis is incomplete or coronary flow is not restored, clinicians may switch to or add other reperfusion strategies, such as urgent coronary intervention (angioplasty/stenting) depending on availability and timing. Treatment decisions depend on ongoing symptoms, vital signs, ECG findings, and follow-up imaging/lab markers.
Retavase vs. alteplase (tPA): what’s the difference?
Retavase (reteplase) and alteplase are both thrombolytics used for acute myocardial infarction, but they differ in molecular design and administration patterns. These differences can affect dosing schedules and practicality in certain treatment settings. Choice between them follows local guidelines and availability.
Is Retavase still commonly used, and what alternatives exist?
Use depends on country-specific availability and guideline preferences. In many settings, reperfusion strategies may include thrombolysis with another agent or primary percutaneous coronary intervention (PCI), based on timing from symptom onset and healthcare resources.
What’s the cost or availability of Retavase?
Pricing and access vary widely by region and insurer. Availability may also depend on whether the product is stocked by hospitals and how procurement is handled locally.
Sources
I don’t have any provided source material to cite in this chat. If you share the text or link you want me to base the answer on (e.g., the Retavase label, a guideline excerpt, or a medical database page), I can produce a properly cited, more specific answer.